InFocus Capital Partners

Visibly provides digital vision care solutions and online vision test services. The company's products include eyewear and contact lenses, providing an online option for vision testing. Visibly serves e-commerce employers, eye care providers, insurance providers, online healthcare platforms, and optical retail.

Stuart Therapeutics is a biotechnology company that offers PolyCol, a therapeutic platform for ophthalmic indications. PolyCol’s unique method of action results in accelerated healing and recovery in various ophthalmic disease states and offers a new way to address indications such as dry eye disease, dry age related macular degeneration, and glaucoma. PolyCol is based on patented research from a major U.S. university, combined with additional intellectual property acquired by Stuart Therapeutics. The company has developed applications for PolyCol in treating certain ophthalmic, gastrointestinal, inflammatory, and oncology conditions.

ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. It was founded in 2011 and is headquartered in Ann Arbor, Michigan.

Re-Vana Therapeutics is a ocular pharmaceuticals & drug delivery company focused on the development and commercialisation of innovative long-acting, biodegradable drug delivery platforms to address ophthalmic conditions such as age-related macular degeneration (AMD), diabetic retinopathy (DR), glaucoma and ocular infections. Their delivery platforms enable tailored delivery of therapeutics for long-term and can be administered by various routes to the eye. By using their platform technologies, delivery of a broad range of molecules including proteins, peptides, and small molecules can be achieved from 1 week to 1 year. The platform technologies are based on FDA-approved polymers. Their injectable platform, OcuLief™, can be tailored for the treatment of AMD and DR to achieve a long-term release of anti-vascular endothelial growth factors (anti-VEGF) or corticosteroids for 1-12 months. Their preformed platform, EyeLief™, can be tailored for the treatment of Glaucoma and retina diseases, to achieve a long-term release of small or large molecules for 6 months or more. The design strategy of Re-Vana revolves around increasing patient compliance by reducing pain and frequency of treatment, lowering side effects by controlled drug release, and cost saving for health care providers and pharmaceutical companies.

Mojo Vision is focused on developing and commercializing high-performance micro-LED display technology for consumer, enterprise, and government applications. The company combines breakthrough technology, leading display and semiconductor expertise, and an advanced 300mm manufacturing process to deliver on the promise of micro-LED displays. Mojo’s proprietary quantum-dot technology brings full-color capability to its display platform and meets the superior performance demands for all form factors. Mojo Vision developed the world’s smallest, densest dynamic display for the first AR smart contact lens and is now applying this innovation and expertise to lead the disruption of the $160 billion display industry. Mojo Vision was founded in 2015 and headquartered in Saratoga, California.

ONL Therapeutics is a biopharmaceutical company dedicated to protecting vision through the protection of photoreceptors. It was founded in 2011 and is headquartered in Ann Arbor, Michigan.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.

QURA develops a series of ultra-miniature implantable devices/tools to monitor physiological pressure changes. These miniaturized tools will have the potential to transform physiologic monitoring in biomedicine and other applications. In the long term, they envision networks of smart, miniaturized tools that communicate and respond to each other in real-time. Networked devices will interact to both monitor disease and administer timely treatments. The development of these devices has great potential to revolutionize both research abilities and human clinical treatment. It was founded in 2015 and is headquartered in Framingham, Massachusetts.

Alievio is a North Carolina-based innovative glaucoma medical device company. The company has introduced the first glaucoma therapy that will not only circumvent the complications present with glaucoma surgery. It also provides ophthalmologists with the first tool that can stop the progression of glaucoma.

Trefoil is a biotechnology company that brings forward novel engineered FGF-1 compounds to treat endothelial cell-mediated diseases, including Fuchs dystrophy and other serious endothelial cell diseases. The eFGF-1 technology platform to develop first-in-class regenerative pharmacologic treatments for corneal diseases, which debilitating and cause a significant amount of preventable blindness throughout the world. Trefoil focuses on a topical eye drop formulation of TTHX1114 for the treatment of ulcerative conditions on the front surface of the cornea which leads to corneal scarring and substantial loss of vision. The company's mission is to improve human health and create new therapies using drugs developed with protein engineering. The management team at Trefoil has more than 100 years of pharmaceutical development and commercialization experience. As an early-stage development company, Trefoil has been recognized by the biopharmaceutical funding community through the CONNECT Springboard business plan program award and the Southeast Biotechnology Early Company Competition.